Trial intelligence / Profile preview

Surufatinib + Octreotide Microspheres as First-Line Therapy in Unresectable or Metastatic Neuroendocrine Tumors

ChiCTR2600124258Phase 2Not yet recruiting

Sponsor

Shandong First Medical University

Start

May 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1